What Can You Expect from the 9th Antifibrotic Drug Development Summit?
As the first MASH approval and IPF Phase 3 wins reset efficacy benchmarks, the 9th Antifibrotic Drug Development Summit is the industry’s only forum to translate these successes into actionable discovery and R&D strategies across fibrotic diseases. Through 20+ expert-led sessions, explore how leaders are:
Leveraging Advances in Omics Technologies
Uncover novel targets by mapping fibroblast-immune crosstalk with single-cell and spatial transcriptomics, accelerating first-in-class mechanism discovery.
Designing a Preclinical Package
Optimize chronic fibrosis models endpoints to derisk candidates before IND, aligning with recent Boehringer Ingelheim’s Phase 3 trial design.
Advancing Imaging & Biomarkers
Replace biopsies with collagen PET tracers and proteomic panels to quantify fibrosis reversal and stratify F2-F3 MASH subpopulations for clinical trials.
Reversing Translation from Phase 2
Decode lessons from GRI Bio’s NKT cell therapy and Alentis’ anti-Claudin-1 mAbs to refine preclinical models and biomarker strategies for faster Phase 2b readiness.
Uncovering emerging Innovations
Explore ADCs, mRNA therapies, and pan-fibrotic mechanisms to compete in a landscape reshaped by Madrigal’s Resmetirom and Lilly’s $99M Mediar deal.
Deep-Dive Workshops:
Discover the optimal preclinical models for chronic and progressive fibrosis modeling, dive deeper into the mechanistic complexities of fibroblast biology across indications, and progress toward transforming pan-antifibrotics from fiction to fact.
Clinical Case Studies:
Learn from reverse-translated Phase 2 data to extract lessons on patient stratification and biomarker-driven endpoints and refine Phase 2 protocols to mirror successful trials, from GRI Bio (NKT cell therapy) and Alentis (anti-Claudin-1 mAbs).
Cross-Fibrosis Panels:
Debate on pan-antifibrotics to compare organ-specific vs. shared mechanisms and prioritize targets with the broadest commercial potential, with AbbVie, Gilead, and Novartis.
Download the Full Event Guide to Discover:
- 80+ industry leaders from top pharma, biotech, and academic organisations
- Actionable strategies across IPF, MASH, kidney, cardiac, and gut fibrosis, all in one place
- Exclusive data from recent approvals and Phase 2 successes
- Cutting-edge science including spatial omics, ADCs, and collagen-targeted PET imaging with pioneers
- 8+ hours of tailored networking opportunities
